| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Biotechnology
News
|
Press Release:
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences
 Dr. Hall has also accepted an invitation to provide a practical overview of the company's proprietary targeting technology and the application of this highly advanced biotechnology in the development of new products for cancer therapy at the upcoming 2nd International Congress of Nanobiotechnology & Nanomedicine, NanoBio2007. The C21 BioVentures Conference, which will be held in Monterey Bay, Calif. May 22-24, 2007, showcases cutting-edge private biotechnology and pharmaceutical companies that are developing superior technologies and products in healthcare and healthcare related areas, and offers them a forum to reach top venture capitalists and key decision makers from leading pharmaceutical and biotechnology companies worldwide. The pronounced visibility that C21 offers will provide an opportunity for Epeius to discuss global partnering initiatives and the company's plans to expedite the international development of Rexin-G. The NanoBio2007 Conference will be held in San Francisco, Calif. June 18- 21, 2007 and will highlight innovative scientific R & D in nanotechnology, as well as business and investment opportunities in the emerging Nanomedicine industry. Epeius, with its best-of-breed targeting technology, and its lead product incontrovertibly validated in the clinic, is well positioned to leverage the positive attributes of both genetic medicine and applied nanotechnology while also offering a novel, safe, and effective medical technology platform with which to engineer a wide variety of anti-cancer agents, targeted cancer vaccines, and cancer diagnostic/imaging products. The powerful anti-cancer agent Rexin-G, the first tumor targeted genetic medicine developed by Epeius Biotechnologies, has received Orphan Drug Status from the FDA based on unprecedented demonstrations of single-agent efficacy in treating pancreatic cancer. Subsequently, the company has gained federal support to continue their landmark clinical trials in the US using intravenous infusions of Rexin-G for treating this intractable metastatic cancer. Further, Rexin-G has gained Expanded Access status in the Philippines for treating all solid tumors that are resistant to chemotherapy - other focus areas include metastatic breast cancer, bone and soft tissue sacoma, lung cancer, colon cancer, skin cancer, and malignant melanoma. About Epeius Biotechnologies Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries-thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product. To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for partnership or clinical trials, please visit us at epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies
Send2Press® is the originating wire service for this story. Terms of Use. © Epeius Biotechnologies. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Epeius Biotechnologies), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Epeius Biotechnologies.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Epeius Biotechnologies : » Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences, Dr. Frederick L. Hall, Epeius, Biotechnologies, 9th annual C21 BioVentures Conference, targeted genetic medicine developed to treat metastatic cancer, NanoBio2007 Conference, powerful anti-cancer agent, Orphan Drug Status from the FDA, soft tissue sacoma, lung cancer, colon cancer, skin cancer, press release, May 15, 2007. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 4594 times (1 today, 2 this week, 14 this month, 43 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)